US FDA approves Eliquis (apixaban) to reduce the risk of blood clots following hip or knee replacement surgery

17-03-2014 Business Wire HealthComments (0)

Bristol-Myers SquibbEliquisPharmaceuticalUSA

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. “Today’s FDA approval of Eliquis for DVT prophylaxis in patients who have undergone hip

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top